Aptiv reported record fourth-quarter revenue of $5.2 billion, a 3% increase, as the automotive technology leader prepares to spin off its Electrical Distribution Systems business as the independent company Versagen on April 1, 2026.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
In a bid to boost the global competitiveness of Indian accounting and advisory firms, the government has announced a dual-pronged reform: simplifying the 'accountant' definition under Safe Harbour Rules and merging tax computation standards with financial reporting norms.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
Minerals 260 (ASX:MI6) has significantly upgraded the resource estimate at its Bullabulling gold project to 4.5 million ounces, bolstered by strong drilling results and a solid cash position. The expansion shifts focus to the upcoming pre-feasibility study and execution risks as the company targets key development decisions by 2026.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
After two punishing years, GitLab's shares have been battered by fears over AI's impact on coding. But with a strategic pivot to an AI-powered development platform and a resilient business model, 2026 could be the year the company turns the narrative around.
President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank has ignited market speculation over the future path of interest rates, with analysts divided on whether his leadership would mean more cuts or a return to hawkish restraint.
Visa is aggressively expanding its footprint beyond traditional card payments, launching new initiatives in stablecoin settlements, renter-focused commerce, and streamlined crypto-to-fiat conversions. These partnerships aim to embed Visa's network into the burgeoning worlds of blockchain-based finance and essential housing expenditures.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
President Trump is expected to nominate former Fed governor Kevin Warsh as the next Federal Reserve Chair, a move that could signal a pivot toward aggressive rate cuts paired with a reduction of the central bank's balance sheet, reshaping the landscape for markets and cryptocurrencies.
Heightened volatility and extreme fear grip the crypto market, setting the stage for potential mass liquidations in SOL, HYPE, and TRX. Traders on both sides of the fence are bracing for impact.
